Loading...
Docoh

Inotiv (NOTV)

Bioanalytical Systems, Inc., operating as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market.

Company profile

Ticker
NOTV
Exchange
Website
CEO
Robert Leasure
Employees
Incorporated
Location
Fiscal year end
Former names
BIOANALYTICAL SYSTEMS INC
SEC CIK
Subsidiaries
Bronco Research ...
IRS number
351345024

NOTV stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 Aug 22
12 Aug 22
30 Sep 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Sep 21 Sep 20 Sep 19 Sep 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 21.72M 21.72M 21.72M 21.72M 21.72M 21.72M
Cash burn (monthly) 8.58M 11.27M (no burn) 6.19M 3.14M 224.25K
Cash used (since last report) 12.49M 16.39M n/a 9M 4.57M 326.31K
Cash remaining 9.23M 5.32M n/a 12.72M 17.15M 21.39M
Runway (months of cash) 1.1 0.5 n/a 2.1 5.5 95.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Apr 22 Fernanda Beraldi Employee Stock Option Common Stock Grant Acquire A No No 25.28 2,500 63.2K 2,500
1 Apr 22 Davis Gregory Cole Common Stock Grant Acquire A No No 0 4,275 0 41,958
1 Apr 22 Johnson Richard Allen Common Stock Grant Acquire A No No 0 4,275 0 71,958
1 Apr 22 Neff R Matthew Common Stock Grant Acquire A No No 0 4,275 0 65,388
1 Apr 22 Scott Cragg Common Stock Grant Acquire A No No 0 4,275 0 4,715
70.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 98 103 -4.9%
Opened positions 21 30 -30.0%
Closed positions 26 15 +73.3%
Increased positions 43 34 +26.5%
Reduced positions 20 32 -37.5%
13F shares Current Prev Q Change
Total value 531.03M 737.08M -28.0%
Total shares 17.89M 18.06M -1.0%
Total puts 0 0
Total calls 8.6K 0 NEW
Total put/call ratio
Largest owners Shares Value Change
P2 Capital Partners 2.95M $77.15M 0.0%
Jermyn Street Associates 2.8M $153.28M 0.0%
Iszo Capital 1.28M $0 0.0%
Ophir Asset Management Pty 1.05M $27.6M +143.9%
BLK Blackrock 983.8K $25.76M +6.2%
Vanguard 862.55K $22.58M +1.6%
JHG Janus Henderson 743.45K $19.46M +34.9%
Davidson Kempner Capital Management 591.64K $13.78M 0.0%
Pembroke Management 498.03K $13.04M +4.4%
Renaissance Technologies 477.77K $12.51M -7.5%
Largest transactions Shares Bought/sold Change
Iszo Capital Management 264.6K -1.01M -79.3%
Next Century Growth Investors 0 -695.18K EXIT
Ophir Asset Management Pty 1.05M +621.89K +143.9%
Portolan Capital Management 390.99K -337.41K -46.3%
Venator Capital Management 285K +205K +256.3%
Thrivent Financial For Lutherans 192.98K +192.98K NEW
JHG Janus Henderson 743.45K +192.29K +34.9%
Loomis Sayles & Co L P 161.72K +161.72K NEW
Boothbay Fund Management 149.58K +149.58K NEW
Rice Hall James & Associates 107.04K +107.04K NEW

Financial report summary

?
Risks
  • Our business, results of operations, financial condition, cash flows and stock price have and may continue to be adversely affected by pandemics, epidemics or other public health emergencies, such as the recent outbreak of COVID-19.
  • We depend on the pharmaceutical and biotechnology industries.
  • A reduction in research and development budgets at pharmaceutical and biotechnology companies may adversely affect our business.
  • We rely on a limited number of key clients, the importance of which may vary dramatically from year to year, and a loss of one or more of these key clients may adversely affect our operating results.
  • We operate in a highly competitive industry.
  • The majority of our clients’ contracts can be terminated upon short notice.
  • We may bear financial risk if we underprice our contracts or overrun cost estimates.
  • Providing CRO services creates a risk of liability.
  • Our business uses biological and hazardous materials, which could injure people or violate laws, resulting in liability that could adversely impact our financial condition and business.
  • Our animal populations may suffer diseases that can damage our inventory, harm our reputation, result in decreased sales of our services or research products or result in other liability.
  • Our products business depends on our intellectual property.
  • We have experienced periods of losses and financial insecurity.
  • Our failure to comply with the terms of our existing credit agreement could result in an event of default that could materially adversely affect our business, financial condition and results of operations.
  • Changes in government regulation or in practices relating to the pharmaceutical industry could change the demand for the services we provide.
  • Any failure by us to comply with existing regulations could harm our reputation and operating results.
  • Privacy regulations could increase our costs or limit our services.
  • Our future success depends on our ability to keep pace with rapid technological changes that could make our services and products less competitive or obsolete.
  • We may incur expenses on potential products that we never successfully develop or commercialize.
  • We may be at risk of cyber-attacks or other security breaches that could compromise sensitive business information, undermine our ability to operate effectively and expose us to liability, which could cause our business and reputation to suffer.
  • Hardware or software failures, delays in the operations of our computer and communications systems or the failure to implement system enhancements could harm our business.
  • Our share price could continue to be volatile and our trading volume may fluctuate substantially.
  • Anti-takeover provisions in our organizational documents and under Indiana law may discourage or prevent a change in control, even if a sale of us would benefit our shareholders, which could cause our stock price to decline and prevent attempts by shareholders to replace or remove our current management.
  • If we are unable to maintain listing of our securities on the NASDAQ Capital Market or another reputable stock exchange, it may be more difficult for our shareholders to sell their securities.
  • We have never paid cash dividends and currently do not intend to do so.
  • We have and may further expand our business through acquisitions, which exposes us to various risks. Our recent acquisitions pose certain incremental risks to the Company.
  • The Company may fail to realize anticipated strategic and financial benefits from recent acquisitions.
  • Our due diligence of our recently acquired businesses may not have identified all pertinent risks, which could materially affect our business, financial condition, liquidity and results of operations.
  • The loss of key personnel could adversely affect our business.
  • We rely on third parties for important services.
  • Unfavorable general economic conditions may materially adversely affect our business.
Management Discussion
  • Revenues for the fiscal year ended September 30, 2021 increased 48.2% to $89,605 compared to $60,469 for the fiscal year ended September 30, 2020.
  • Our Services revenue increased 50.1% in fiscal 2021 to $85,832 compared to $57,177 for the prior fiscal year. Nonclinical services revenues increased due to internal growth year over year as well as the acquisition of substantially all
  • Cost of revenue for the year ended September 30, 2021 was $59,450 or 66.3% of revenue compared to $42,232 or 69.8% of revenue for the prior fiscal year.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: admission, al, bacterial, baseline, Battery, captioned, closure, corrective, Cumberland, declaratory, decommission, denial, discrete, disposal, DOJ, drew, Dublin, entitled, exit, exited, Good, greatly, grew, Grobler, healthcare, imposition, Ind, lawsuit, merit, move, mutation, mutually, Northern, outcome, pertaining, plant, Practice, prejudice, progressed, promulgated, prosecution, Protypia, putative, refrain, reputation, seizure, site, sought, steadfast, system, tailor, tissue, underfunded, unspecified, VA, vacate, vendor, Virginia, warning, warrant, Western, workforce, wrongdoing, xvii
Removed: arrangement, capex, chemical, comparable, construction, contemplated, formal, greater, perform, receivable, recently, reflecting, travel, utilization